Candel Therapeutics, Inc. (Nasdaq: CADL) announced the publication of final phase 2a clinical trial results for aglatimagene besadenovec plus valacyclovir ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE